Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Return on Equity (2016 - 2025)

Historic Return on Equity for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 0.43%.

  • China Pharma Holdings' Return on Equity rose 2500.0% to 0.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.43%, marking a year-over-year increase of 2500.0%. This contributed to the annual value of 0.62% for FY2024, which is 1000.0% down from last year.
  • As of Q3 2025, China Pharma Holdings' Return on Equity stood at 0.43%, which was up 2500.0% from 0.54% recorded in Q2 2025.
  • China Pharma Holdings' 5-year Return on Equity high stood at 0.39% for Q1 2021, and its period low was 1.12% during Q4 2022.
  • Its 5-year average for Return on Equity is 0.64%, with a median of 0.59% in 2023.
  • As far as peak fluctuations go, China Pharma Holdings' Return on Equity soared by 19900bps in 2021, and later plummeted by -5900bps in 2022.
  • Over the past 5 years, China Pharma Holdings' Return on Equity (Quarter) stood at 0.53% in 2021, then tumbled by -111bps to 1.12% in 2022, then skyrocketed by 59bps to 0.45% in 2023, then plummeted by -46bps to 0.66% in 2024, then surged by 35bps to 0.43% in 2025.
  • Its Return on Equity was 0.43% in Q3 2025, compared to 0.54% in Q2 2025 and 0.62% in Q1 2025.